Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEN SHE Study
PACTR202002647375231Phase 4Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of human papillomavirus type 16 L1 capsid protein antigen, recombinant human papillomavirus 9-valent vaccine and meningococcal vaccine (SPbSRIVS) in human papillomavirus infection and Cervical Cancer (CC) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Persistent vaccine-type specific HPV infection at months 18 and 36, Quantitative antibody response at months 1 and 24 and 1 more. Status: unknown.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenrecombinant human papillomavirus 9-valent vaccinemeningococcal vaccine (SPbSRIVS)
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on PACTR202002647375231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202002647375231.